Streptozocin for treatment of pancreatic islet cell tumors in dogs: 17 cases (1989–1999)

Moore, Antony S.; Nelson, Richard W.; Henry, Carolyn J.; Rassnick, Kenneth M.; Kristal, Orna; Ogilvie, Gregory K.; Kintzer, Peter P.

doi:10.2460/javma.2002.221.811

Cited by 54 publications

(38 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unfortunately, medical management has minimal efficacy and the potential for severe side effects. Other drugs that have been evaluated include various chemotherapeutic agents such as streptozotocin and alloxan, which have direct effects on the pancreatic beta cells (Moore and others 2002).…”

Section: Discussionmentioning

confidence: 99%

Insulinoma in a cat

Greene

Bright

2007

J of Small Animal Practice

View full text Add to dashboard Cite

A 14-year-old domestic shorthair cat was presented with hypoglycaemia and seizures of several weeks duration. Bloodwork revealed hypoglycaemia (1.83 mmol/l; reference range 4.22-8.05 mmol/l) with concurrent normal insulin levels (171 pmol/l; reference range 72-583 pmol/l). An insulinoma was suspected and medical and dietary management were attempted with minimal success. An exploratory laparotomy was performed and a single, well-defined mass was found within the left lobe of the pancreas. The mass was removed and histologically classified as an islet cell carcinoma, consistent with an insulinoma. The cat had an episode of presumed postoperative pancreatitits, but recovered with appropriate treatment. The cat has had no clinical signs of recurrence of greater than 32 months postsurgery. There are only four cases of insulinoma in cats reported in the literature. All prior insulionomas reported were in older cats and were malignant in character, which is similar to the reports in the dog. This case is unique because of the apparent lack of local recurrence and development of metastatic disease, leading to the prolonged survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Insulinoma in a cat

Greene

Bright

2007

J of Small Animal Practice

View full text Add to dashboard Cite

show abstract

“…Fifty-eight treatments were administered to 17 dogs with an insulin-secreting tumor at variable times after surgery (Moore et al, 2002). Sixteen of 17 dogs had metastatic disease.…”

Section: Somatostatin Therapymentioning

confidence: 99%

“…However, a viable treatment protocol using streptozotocin in dogs has been described, and studies to determine its value in the treatment of insulin-secreting tumors have been reported (Moore et al, 2002;Northrup et al, 2013). The potential for serious adverse reactions has limited the use of these drugs for the treatment of insulinsecreting tumors in dogs.…”

Section: Introductionmentioning

confidence: 99%

Beta-Cell Neoplasia: Insulinoma

Nelson¹

2015

Canine and Feline Endocrinology

Self Cite

View full text Add to dashboard Cite

“…Nevertheless, surgery alone is unlikely to be curative due to approximately 50% of dogs having metastatic disease, and most dogs develop progressive disease leading to recurrent hypoglycemia and secondary neuroglycopenia [1-3, 9, 10]. Therefore, medical treatments are warranted in attempt to inhibit progression of metastatic disease, ameliorate clinical signs, and extend survival times while maintaining quality of life [1][2][3][8][9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

WITHDRAWN: Management of canine insulinomas with toceranib phosphate: 30 cases (2009-2019)

Sheppard‐Olivares¹,

Bello²,

Johannes³

et al. 2020

Preprint

View full text Add to dashboard Cite

BACKGROUNDInsulinomas are the most common tumour of the endocrine pancreas in dogs. These are malignant tumours with a high metastatic rate and limited efficacious chemotherapeutic options available. Recent literature supports the use of the multi-receptor tyrosine kinase inhibitor sunitinib malate for treatment of metastatic insulinoma in people. Toceranib phosphate is a veterinary targeted therapy that may provide benefit in treatment of canine insulinomas. The primary objectives of this retrospective study were to describe the control of clinical signs, response to toceranib in the case of measurable disease, and outcomes of toceranib therapy for canine insulinoma. A secondary objective was to describe the adverse effects of toceranib in dogs with insulinoma.RESULTSA medical record search identified 30 dogs diagnosed with insulinoma and treated with toceranib at five university hospitals and eight veterinary specialty referral hospitals. A majority (66.7%) of dogs with measurable disease experienced either complete response (CR), partial response (PR), or stable disease (SD) for a minimum of 10 weeks with toceranib therapy. The overall median progression free interval (PFI) was 561 days (95% confidence interval: [246, 727 days]). The overall medial survival time (OST) was 656 days [310, 1045 days]. Larger dogs were at increased risk for disease progression (P = 0.0310) and death (P = 0.0064), with every 1 kg increase in body weight resulting in hazard ratios (HRs) of 1.045 [1.003, 1.084] and 1.05 [1.012, 1.090], respectively. In addition, time to disease progression was associated with use of therapies prior to toceranib (P = 0.0050) and type of veterinary practice (P = 0.0025). The most common adverse events with toceranib therapy were grade 1 or 2 gastrointestinal toxicities.CONCLUSIONSClinical benefit was reported in the majority of dogs diagnosed with insulinoma treated with toceranib, but randomized, prospective studies are needed to assess and quantify the effect of this therapy. The most commonly observed adverse events (AEs) were grade 1 or 2 gastrointestinal AEs.

show abstract

Streptozocin for treatment of pancreatic islet cell tumors in dogs: 17 cases (1989–1999)

Abstract: Results suggest that streptozocin can be administered safely to dogs at a dosage of 500 mg/m2, IV, every 3 weeks when combined with a protocol for induction of diuresis and may be efficacious in the treatment of dogs with metastatic pancreatic islet cell tumors.

Cited by 54 publications

References 20 publications

Insulinoma in a cat

Insulinoma in a cat

Beta-Cell Neoplasia: Insulinoma

WITHDRAWN: Management of canine insulinomas with toceranib phosphate: 30 cases (2009-2019)

Contact Info

Product

Resources

About